Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2022 16:14 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results

Initiated Phase 1/1b clinical trial of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab), for the treatment of patients with...
April 20, 2022 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
April 20, 2022 09:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022

SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
April 08, 2022 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio

ILT2, ILT4, ILT3 and LAIR1 are myeloid checkpoints that may play a central role in establishing an immune-suppressive state in the tumor microenvironmentNGM707, NGM831 and NGM438 are all engineered to...
March 31, 2022 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

Dose-escalation and dose-expansion trial evaluating potential of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) initiated and...
March 21, 2022 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022

--The four-part series titled the “Explorer Series” will showcase NGM Bio’s discovery engine, myeloid reprogramming and checkpoint inhibition portfolio and program for the treatment of geographic...
March 08, 2022 16:13 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting

Oral presentation to showcase NGM Bio’s in vitro and in vivo research demonstrating potential advantages of dual ILT2/ILT4 inhibition with NGM707, currently in Phase 1/2 trialLate-breaking poster...
March 01, 2022 16:06 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

Advanced programs across NGM Bio’s pipeline in retinal diseases, oncology and liver and metabolic diseases during the fourth quarter and beginning of 2022: Obtained Fast Track designation from the...
February 28, 2022 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Participate in the Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
February 07, 2022 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...